Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study

Barber, Neil; Zhang, X.; Zhu, Guohua; Pramanik, Rashida; Barber, Julie; Martin, Francis L.; Morris, Jeremy; Muir, Gordon

doi:10.1038/sj.pcan.4500895

Cited by 56 publications

(38 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of relevance to prostate cancer, lycopene has been shown to inhibit DNA synthesis (Barber et al, 2006). Lycopene also inhibits growth of hormone-dependent LNCaP and C4-2 prostate cancer cell lines without affecting PSA mRNA expression (Peternac et al, 2008), and increases expression of PPARgamma and LXRalpha in LNCaP cells .…”

Section: In Vitro Datamentioning

confidence: 99%

Dietary Manipulation for Therapeutic Effect in Prostate Cancer

Gano¹,

Scott²,

Bucci³

et al. 2012

Cancer Prevention - From Mechanisms to Translational Benefits

View full text Add to dashboard Cite

Section: In Vitro Datamentioning

confidence: 99%

Dietary Manipulation for Therapeutic Effect in Prostate Cancer

Gano¹,

Scott²,

Bucci³

et al. 2012

Cancer Prevention - From Mechanisms to Translational Benefits

View full text Add to dashboard Cite

“…Three before-after studies reported a significant reduction in PSA after intervention, [30][31][32] whereas two did not see any change in PSA. 33,34 In the study by Kim et al, 35 32 prostate cancer patients awaiting prostatectomy and treated with lycopene supplementation (tomato sauce 30 mg per day) for 3 weeks were compared with 34 controls also undergoing prostatectomy for prostate cancer.…”

Section: Change In Psa Levelsmentioning

confidence: 99%

“…Five had no control (before-after design) [30][31][32][33][34] and one had an unmatched control group; 35 it was unclear how the control group was selected. The remaining two studies were RCTs, but one 36 was very small and included 35 patients with data available for analysis from only 26 patients.…”

Section: Lycopene Supplementation and Prostate Cancer Progression F Hmentioning

confidence: 99%

See 1 more Smart Citation

Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review

Haseen

Cantwell

O’Sullivan

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Lycopene has a chemopreventive effect against prostate cancer but its role in prostate cancer progression is unknown; many patients increase their intake of lycopene, although there are no evidence-based guidelines to suggest an effect. Our objective was to conduct a systematic review of literature to evaluate the association between lycopene intake and prostate cancer progression. MEDLINE, EMBASE CINAHL Plus, Web of Science, AMED and CENTRAL databases were systematically searched using terms for lycopene and prostate cancer progression to identify studies published before January 2009. Eight intervention studies were identified (five with no control group; one with an unmatched control group; and two randomized controlled trials (RCTs)). An inverse association was observed between lycopene intake and PSA levels in six studies. The rates of progression measured by bone scan in one RCT were lower in the intervention group. Lycopene resulted in lowering cancer-related symptoms (pain, urinary tract symptoms), and severe toxicity or intolerance was not evident. However, the evidence available to date is insufficient to draw a firm conclusion with respect to lycopene supplementation in prostate cancer patients and larger RCTs are required in broader patient groups.

show abstract

“…Short-term lycopene supplementation in men with localized prostate cancer was shown to lower serum prostate-specific antigen (PSA) levels (as a measure of prostate cancer progression) over 3 weeks to 1 year, though only two of four studies were placebo-controlled. 15,[22][23][24] In the only epidemiologic study to date, in 1,202 men in the Health Professionals Follow-up Study with localized/regional prostate cancer, being in the highest quartile of postdiagnosis tomato sauce intake, compared to being in the lowest quartile, was associated with lower risk of prostate cancer progression (defined as PSA recurrence, metastasis or prostate cancer death) [hazard ratio (HR) 5 0.56, 95% confidence interval (CI) 0.38-0.82]. 6 No previous study has examined the association of dietary lycopene intake or tomato products with prostate cancer-specific mortality (PCSM).…”

mentioning

confidence: 99%

Lycopene, tomato products and prostate cancer‐specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Wáng

Jacobs

Newton

et al. 2016

Intl Journal of Cancer

View full text Add to dashboard Cite

While dietary lycopene and tomato products have been inversely associated with prostate cancer incidence, there is limited evidence for an association between consumption of lycopene and tomato products and prostate-cancer specific mortality (PCSM). We examined the associations of prediagnosis and postdiagnosis dietary lycopene and tomato product intake with PCSM in a large prospective cohort. This analysis included men diagnosed with nonmetastatic prostate cancer between enrollment in the Cancer Prevention Study II Nutrition Cohort in 1992 or 1993 and June 2011. Prediagnosis dietary data, collected at baseline, were available for 8,898 men, of whom 526 died of prostate cancer through 2012. Postdiagnosis dietary data, collected on follow-up surveys in 1999 and/or 2003, were available for 5,643 men, of whom 363 died of prostate cancer through 2012. Cox proportional hazards regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for PCSM. Neither prediagnosis nor postdiagnosis dietary lycopene intake was associated with PCSM (fourth vs. first quartile HR 5 1.00, 95% CI 0.78-1.28; HR 5 1.22, 95% CI 0.91-1.64, respectively). Similarly, neither prediagnosis nor postdiagnosis consumption of tomato products was associated with PCSM. Among men with high-risk cancers (T3-T4 or Gleason score 8-10, or nodal involvement), consistently reporting lycopene intake median on both postdiagnosis surveys was associated with lower PCSM (HR 5 0.41, 95% CI 0.17-0.99, based on ten PCSM cases consistently median intake) compared to consistently reporting intake < median. Future studies are needed to confirm the potential inverse association of consistently high lycopene intake with PCSM among men with high-risk prostate cancers.Prostate cancer is the most commonly diagnosed cancer, and the second leading cause of cancer death among men in the United States. 1 There are nearly 3 million prostate cancer survivors currently living in the United States, accounting for 20% of all cancer survivors, and the number is still increasing with 220,000 new cases diagnosed each year. 2 Despite a generally good prognosis, death from prostate cancer, even for men diagnosed with localized prostate cancer, is still a concern. 3 Although localized prostate cancer is mostly indolent, local progression and distant metastasis can develop over the long term and cause prostate cancer death. 4 In addition, men with high-grade tumors (Gleason score 8-10) are at least four times as likely to die from prostate cancer as men with low-grade tumors (Gleason score 2-6). 5 Although data are still limited, a growing number of studies suggest that longterm postdiagnosis diet plays a role in prostate cancer progression and eventually prostate cancer mortality. [6][7][8][9] Lycopene, found predominantly in tomato products, is a major carotenoid widely distributed in the human body. Lycopene accumulates in several key organs including the prostate gland. 10 Lycopene is hypothesized to have anticarcinogenic effects primarily due to its antioxi...

show abstract

Lycopene inhibits DNA synthesis in primary prostate epithelial cells in vitro and its administration is associated with a reduced prostate-specific antigen velocity in a phase II clinical study

Cited by 56 publications

References 24 publications

Dietary Manipulation for Therapeutic Effect in Prostate Cancer

Dietary Manipulation for Therapeutic Effect in Prostate Cancer

Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review

Lycopene, tomato products and prostate cancer‐specific mortality among men diagnosed with nonmetastatic prostate cancer in the Cancer Prevention Study II Nutrition Cohort

Contact Info

Product

Resources

About